Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221578 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
A Phase 3 study of Social Anxiety Disorder (SAD), sponsored by Vanda Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT07221578: Recruiting Phase 3 study of Social Anxiety Disorder (SAD), sponsored by Vanda Pharmaceuticals.
NCT07221578 is a Phase 3 study of Social Anxiety Disorder (SAD) that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 500 participants, above the 103-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (385% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07221578, a Phase 3 study of Social Anxiety Disorder (SAD), is actively recruiting participants, sponsored by Vanda Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.
Primary Outcome
Subjective Units of Distress Scale (SUDS) during performance phase, scored from 0-100 with a higher score indicating higher distress.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VQW-765
Study Locations (20)
California
- Vanda Investigational Site - Encino
- Vanda Investigational Site - Newport Beach
- Vanda Investigational Site - San Diego
- Vanda Investigational Site - San Jose
- Vanda Investigational Site - Walnut Creek
Florida
- Vanda Investigational Site - Jacksonville
- Vanda Investigational Site - Miami
- Vanda Investigational Site - Orlando
- Vanda Investigational Site - Tampa
Arizona
- Vanda Investigational Site - Phoenix
- Vanda Investigational Site - Scottsdale
Georgia
- Vanda Investigational Site - Atlanta
- Vanda Investigational Site - Suwanee
Maryland
- Vanda Investigational Site - Pikesville
- Vanda Investigational Site - Rockville
Missouri
- Vanda Investigational Site - Saint Charles
- Vanda Investigational Site - St Louis
Colorado
- Vanda Investigational Site - Denver
Louisiana
- Vanda Investigational Site - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2027-04 |
| Phase | Phase 3 |
What NCT07221578 shows while recruiting
NCT07221578 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 103-participant average among 5 other Social Anxiety Disorder (SAD) trials with a reported enrollment target (385% higher).
The record links to 1 condition, with Social Anxiety Disorder (SAD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07221578 names 20 study sites across 9 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07221578 about?
NCT07221578 is a clinical study titled "Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder". This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.
What is the current status of trial NCT07221578?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2025-09-22. Estimated completion is 2027-04.
What conditions does trial NCT07221578 study?
This clinical trial studies the following conditions: Social Anxiety Disorder (SAD).
What interventions are being tested in trial NCT07221578?
The interventions under investigation include: Placebo (DRUG), VQW-765 (DRUG).
Who is sponsoring clinical trial NCT07221578?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221578 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety Disorder (SAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
RECRUITING · Phase 3
-
Stepped Care Treatment for Anxiety Resilience
RECRUITING · NA
-
A Study of NTX-1472 in Social Anxiety Disorder
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Nefazodone in the Treatment of Social Phobia
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI